Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
Date:12/16/2008

EMERYVILLE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. (Celtic) has provided an update on XERECEPT(R).

NTI sold the worldwide rights and assets related to XERECEPT to Celtic in November 2005. NTI is entitled to receive milestone payments upon the achievement of certain regulatory approvals, and if XERECEPT is approved for commercial sale, NTI is also entitled to receive profit-sharing payments on sales in the United States and royalties on sales elsewhere in the world.

"We are very pleased at the effort Celtic has applied to this project, bringing it to the point of producing, understanding and presenting solid clinical data to the medical community while simultaneously undertaking a preclinical program to expand the future potential applications of XERECEPT," said Paul E. Freiman, president and chief executive officer. "Further, our partnership has flourished on a personal basis and we both feel each party has added value to the collaboration."

    The text of the press release from Celtic is as follows:

       "Celtic Pharma Announces Update on Status of XERECEPT(R) Program
                            Sale Planned in 2009"

     "New York, London and Bermuda, December 16, 2008 - Celtic Pharmaceutical
     Holdings L.P. ("Celtic Pharma")announced today that the databases have
     been locked and preliminary analyses completed on the two double-blinded
     studies of XERECEPT(R) (corticorelin acetate), as a treatment for
     peritumoral brain edema, as well as an initial database lock on the
     open-label study of XERECEPT's long-term safety and efficacy.

     "The results of these studies are the subject of several abstract
     submissions for the American Society of Clinical Oncolo
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
2. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
3. Neurobiological Technologies Sets Date for First Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
6. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
8. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
9. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
10. Neurobiological Technologies CEO to Retire on December 31, 2008
11. Neurobiological Technologies Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Aneesh Chopra, the nation,s first Chief Technology Officer, will ... on Tuesday, November 9, summit organizers announced today. Chopra ... Technology in the White House Office of Science and ... the Foundation for the National Institutes of Health in ...
... Sept. 8 BioSpecifics Technologies Corp. (Nasdaq: ... collagenase-based products, today announced that BioSpecifics, President, Tom Wegman, ... Annual Healthcare Conference on Wednesday, September 15, 2010, at ... the presentation can be accessed under "Calendar of Events" ...
... Cold Chain MENA 2010 to Focus on Critical Industry Issues -- DUBAI, UAE, September 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:Aneesh Chopra Joins 2010 mHealth Summit as Keynote Speaker 2Cold Chain MENA 2010 to Focus on Critical Industry Issues 2Cold Chain MENA 2010 to Focus on Critical Industry Issues 3Cold Chain MENA 2010 to Focus on Critical Industry Issues 4Cold Chain MENA 2010 to Focus on Critical Industry Issues 5Cold Chain MENA 2010 to Focus on Critical Industry Issues 6
(Date:7/23/2014)... Ind. Spinach gave Popeye super strength, but it ... a group of scientists: the ability to convert sunlight ... physicists are part of an international group using spinach ... by which plants convert the sun,s energy into carbohydrates ... study are part of the most efficient system ever ...
(Date:7/23/2014)... , , , ... , , , , ... lifespan. The idea, they argue, would be to target the... , , ... , , , , ... , , , , , , , Medicine focuses almost entirely on ...
(Date:7/23/2014)... its grip is affecting more than the color of people,s ... a heat-loving amoeba commonly found in warm freshwater bodies, such ... made warmer than usual this year. , A 9-year-old Kansas ... after swimming in several area lakes. The amoeba enters the ... the brain. Nose plugs can lower the odds of this ...
Breaking Biology News(10 mins):Spinach could lead to alternative energy more powerful than Popeye 2Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Diseases of another kind 2
... An experimental vaccine applied the surface of the skin ... Scientists from the Research Institute at Nationwide Children,s ... the 109th General Meeting of the American Society for ... to show that transcutaneous immunization is an effective way ...
... the scourge of Britain,s roads! But now scientists and ... motorists caused by the repair, maintenance and upgrading of ... new technology will allow workers to virtually ,see, underground ... The University of Nottingham on June 11th brings together ...
... University of Minnesota, addressing long-standing conflicts in ecology ... the future of community ecology. The team ... evolutionary relationships among different species phylogenetics ... The work, published in the May issue of ...
Cached Biology News:Preventing ear infections in the future: Delivering vaccine through the skin 2Reducing the roadworks 2Reducing the roadworks 3U of Minnesota research reveals critical role of evolutionary processes in species coexistence 2
... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
Biology Products: